Fig. 1

A 55-year-old male diagnosed with prostatic adenocarcinoma underwent radical prostatectomy in April 2017, and his Gleason score was 3 + 4 = 7. He underwent hormonal therapy until April 2018 and received 1# of radiotherapy to B/L hip and D5-vertebra. He was referred to us for symptomatic pain relief. His baseline pain scoring (VASmax) was 9/10, with maximum pain in the B/L hips. We administered 1.3 GBq of [¹⁷⁷Lu]Lu-DOTA-ZOL and 24-h post-administration, a the 24-h anterior and posterior post-therapy whole-body scans demonstrating avid [¹⁷⁷Lu]Lu-DOTA-ZOL uptake in multiple skeletal sites. b The uptake of [¹⁷⁷Lu]Lu-DOTA-ZOL in the pelvic bone metastases on post-therapy SPECT/CT